NTRB
NutriBand Inc.
$3.53
0.00%
$42.9M
No data for this timeframe.
Vol
Market Cap$42.9M
Cap SizeNano Cap
Inst. Holders4 funds
Inst. Value$948.6K
Inst. Activity0 buys / 1 sells
Press Releases1
Exchange Nasdaq·Sector Orthopedic, Prosthetic & Surgical Appliances & Supplies·Inc. NV·CIK 0001676047·Prev Close $3.53
Recent Activity
Inst.
BANK OF AMERICA CORP — TRIM
106 shares ($481.00)
Inst.
UBS Group AG — DOUBLED
19,637 shares ($138.4K)
Jun 1, 2026
earnings_calendar
NTRB Q1 2027 Earnings Scheduled — 2026-06-01
Mar 30, 2026
Press
Nutriband Inc. announced the selection of a commercial worldwide brand name for its lead product, an abuse-deterrent fen
Impact 3/10
Price Targets
Historical data — last covering-analyst action Jan 2025. No current recommendation available.
$15.00 (Jan 2025)
Current $3.53
Low $15.00
Median $15.00
High $15.00
1 analysts
$15.00
$15.00
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jan 22, 2025 | Noble Capital Markets | INITIATE | Outperform |
| Jul 26, 2022 | Small Cap Consumer Research | MAINTAIN | Buy |
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $920.4K | ADD |
| MORGAN STANLEY | $15.9K | NEW |
| WELLS FARGO & COMPANY/MN | $11.8K | — |
| BANK OF AMERICA CORP | $481.00 | TRIM |
4 institutional holders with $948.6K total value (208,944 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, WELLS. Net selling activity: 1 institutions trimmed/exited vs 0 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 202,738 | $920.4K | 97.0% | ADD +59.7% |
| 2 | MORGAN STANLEY | 3,500 | $15.9K | 1.7% | NEW |
| 3 | WELLS FARGO & COMPANY/MN | 2,600 | $11.8K | 1.2% | — |
| 4 | BANK OF AMERICA CORP /DE/ | 106 | $481.00 | 0.1% | TRIM -46.5% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | TRIM | 198 | 106 | -46.5% | $481.00 | 2025-Q4 |
| UBS Group AG | DOUBLED | 1 | 19,637 | +1963600.0% | $138.4K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 43 | 242 | +462.8% | $1.9K | 2025-Q2 |
| UBS Group AG | NEAR_EXIT | 4,328 | 1 | -100.0% | $8.00 | 2025-Q2 |
| VANGUARD GROUP INC | ADD | 124,590 | 199,027 | +59.7% | $1.2M | 2025-Q1 |
| UBS Group AG | TRIM | 6,241 | 4,328 | -30.7% | $26.5K | 2025-Q1 |
| MORGAN STANLEY | NEW | — | 3,549 | — | $21.8K | 2025-Q1 |
| UBS Group AG | TRIM | 20,352 | 6,241 | -69.3% | $29.4K | 2024-Q4 |
| MORGAN STANLEY | EXIT | 3,200 | 0 | -100.0% | $0.00 | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
No SEC filing reports analyzed yet. Reports are generated when new filings are detected and processed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Jan 2025): 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Jan 2025. No current recommendation available.
$15.00 mean target (Jan 2025)
$15.00 Low
$15.00 High
| Metric | Value |
|---|---|
| Current Price | $3.53 |
| Target Low | $15.00 |
| Target Mean | $15.00 |
| Target Median | $15.00 |
| Target High | $15.00 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q 2026-07-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2027-01-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jan 22, 2025 | Noble Capital Markets | INITIATE | — | Outperform |
| Jul 26, 2022 | Small Cap Consumer Research | MAINTAIN | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 1, 2026
earnings_calendar
NTRB Q1 2027 Earnings Scheduled — 2026-06-01
May 28, 2026
earnings_calendar
NTRB Q1 2027 Earnings Scheduled — 2026-05-28
May 15, 2026
other
Nutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference
AI Products Showcase
Apr 27, 2026
earnings_calendar
NTRB Q4 2026 Earnings After Market Close — 2026-04-27
Apr 22, 2026
other
Nutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel Podcast
CEO Gareth Sheridan appears as guest on the Jack Neel Podcast
Mar 30, 2026
contract
Nutriband Selects Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch
Name chosen for AVERSA Fentanyl commercial product